Updated:
Pulmatrix, Inc.
Pulmatrix paused development of its iSPERSE inhaled-drug candidates while pursuing monetization; its March 2026 Eos merger agreement was conditional.
Overview
Pulmatrix developed inhaled drug candidates using iSPERSE, an engineered dry-powder delivery platform. Its investigational programs addressed migraine and respiratory conditions, including chronic obstructive pulmonary disease and allergic bronchopulmonary aspergillosis. In its annual filing published in February 2026, the company reported that development was paused while it pursued monetization opportunities. Its March 26, 2026 agreement for a proposed Eos merger was subject to approvals and other closing conditions. Its reported principal executive office is in Framingham, MA (United States). For fiscal 2025, ended 2025-12-31, its originally reported results included a net loss of USD 5,162,000; cash used in operations of USD 5,433,000. At that year-end, it reported total assets of USD 4,139,000 and cash and cash equivalents of USD 4,088,000.
Company overview
- Legal name
- Pulmatrix, Inc.
- Former names in filing history
- Ruthigen, Inc. (2013-05-24 to 2015-06-16)
- Classification
- Public company
- Industry (SIC)
- 2834 — Pharmaceutical Preparations
- Headquarters
- Framingham, MA, United States
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 0001574235
Financials
Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.
| Fiscal year | Period end | Revenue | Net income | Total assets | Cash and equivalents | Operating cash flow |
|---|---|---|---|---|---|---|
| FY2025USD | — | -$5.2M | $4.1M | $4.1M | -$5.4M | |
| FY2024USD | $7.8M | -$9.6M | $9.9M | $9.5M | -$10.7M | |
| FY2023USD | $7.3M | -$14.1M | $34.0M | $19.2M | -$16.0M | |
| FY2022USD | $6.1M | -$18.8M | $41.0M | $35.6M | -$19.4M |
Recent SEC filings
| Form | Filed | Period | Filing |
|---|---|---|---|
| 10-Q | 10-Q | ||
| 8-K | 8-K | ||
| S-4 | — | S-4 | |
| 10-K/A | 10-K/A | ||
| 10-Q | 10-Q | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 10-K | 10-K | ||
| 8-K | 8-K | ||
| 8-K | 8-K |
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Research Pulmatrix, Inc. in Altss
Track this company’s investors, transactions and relationships in Altss.